Acurx Pharmaceuticals Inc

ACXP

Company Profile

  • Business description

    Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

  • Contact

    259 Liberty Avenue
    Staten IslandNY10305
    USA

    T: +1 917 533-1469

    https://www.acurxpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4

Stocks News & Analysis

stocks

Fair value upgrade for this ASX income player

Headwinds in listed energy stocks likely to have passed
stocks

The SpaceX IPO and the Elon Musk factor

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks

The ASX’s most shorted stocks in 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,657.502.200.03%
CAC 407,772.4570.500.92%
DAX 4022,562.88262.131.18%
Dow JONES (US)45,206.5439.900.09%
FTSE 10010,127.96160.611.61%
HKSE24,750.79201.09-0.81%
NASDAQ20,760.43187.93-0.90%
Nikkei 22551,885.851,487.22-2.79%
NZX 50 Index12,748.92186.47-1.44%
S&P 5006,337.4631.39-0.49%
S&P/ASX 2008,461.000.100.00%
SSE Composite Index3,923.299.560.24%

Market Movers